King Wealth Management Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

King Wealth Management Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-31,401	Closed	-$317K	–	127
2016 Q3	$317K	Buy	31,401 +519	+2%	+$5.67K	0.16%	80
2016 Q2	$347K	Sell	30,882 -484	-2%	-$6.16K	0.19%	68
2016 Q1	$428K	Buy	31,366 +3,450	+12%	+$49.7K	0.23%	60
2015 Q4	$530K	Buy	27,916 +1,936	+7%	+$42.1K	0.29%	57
2015 Q3	$488K	Buy	+25,980	New	+$442K	0.3%	59

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

King Wealth Management Group's CNCE Position: Q4 2016 in Review

King Wealth Management Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2016, closing a stake of 31,401 shares — an estimated $317K sold.

King Wealth Management Group first reported a position in CNCE in Q3 2015 and held it in 5 quarters. The position peaked at $530K in Q4 2015. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

King Wealth Management Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
King Wealth Management Group sold 31,401 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $317K.
King Wealth Management Group first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 5 quarters.
King Wealth Management Group's Concert Pharmaceuticals, Inc. position peaked at $530K in Q4 2015.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on King Wealth Management Group's 13F filing for Q4 2016, filed 13 Feb 2017.